Financial Performance - Revenue for the six months ended September 30, 2024, was HKD 87,201, a decrease of 14,409 compared to HKD 101,610 for the same period in 2023, representing a decline of approximately 14.2%[5] - The net loss for the period was HKD (18,569), an improvement from HKD (20,019) in the previous year, reflecting a reduction of about 7.2%[5] - Adjusted net loss for the six months ended September 30, 2024, was HKD (11,272), compared to HKD (20,019) in the same period last year, indicating an improvement of approximately 43.7%[5] - Operating loss before depreciation and impairment for the period was HKD (4,016), significantly improved from HKD (15,922) in the previous year, showing a reduction of about 74.8%[5] - The company reported a net loss of HKD 18,569,000 for the six months ended September 30, 2024, compared to a loss of HKD 20,019,000 for the same period in 2023[23] - The company recorded a loss of approximately HKD 18.6 million for the six months ended September 30, 2024, compared to a loss of HKD 20.0 million for the same period in 2023[69] Revenue Breakdown - Income from ophthalmic services was HKD 82,305,000, down 14.2% from HKD 95,832,000 year-on-year[17] - Revenue from refractive surgery decreased by approximately HKD 6.0 million or 10.3% to about HKD 52.0 million for the six months ended September 30, 2024, compared to approximately HKD 58.0 million for the same period in 2023[44] - Revenue from SMILE surgeries decreased by approximately HKD 7.0 million or 22.6% to about HKD 24.0 million for the six months ended September 30, 2024, compared to approximately HKD 31.0 million for the same period in 2023[44] - Revenue from implantable contact lens procedures increased by approximately HKD 9.1 million or 116.7% to about HKD 16.9 million for the six months ending September 30, 2024, compared to approximately HKD 7.8 million for the same period in 2023[45] - Revenue from other eye treatment procedures decreased by approximately HKD 7.6 million or 25.2% to about HKD 22.5 million for the six months ending September 30, 2024, from approximately HKD 30.1 million for the same period in 2023[46] - Revenue from diagnostic and examination services increased by approximately HKD 0.6 million or 9.8% to about HKD 6.7 million for the six months ending September 30, 2024, compared to approximately HKD 6.1 million for the same period in 2023[48] - Revenue from pediatric myopia prevention decreased by approximately HKD 0.7 million or 22.6% to about HKD 2.4 million for the six months ending September 30, 2024, from approximately HKD 3.1 million for the same period in 2023[50] - Other income totaled HKD 2,460,000, a decline of 24.3% compared to HKD 3,253,000 in the previous year[17] Assets and Equity - Total non-current assets as of September 30, 2024, amounted to HKD 64,902, a decrease from HKD 66,955 as of March 31, 2024[7] - Current assets totaled HKD 153,612 as of September 30, 2024, down from HKD 169,208 as of March 31, 2024, reflecting a decrease of approximately 9.2%[7] - Cash and cash equivalents were HKD 122,390 as of September 30, 2024, compared to HKD 141,431 as of March 31, 2024, indicating a decline of about 13.5%[7] - The total equity attributable to the owners of the company was HKD 174,027 as of September 30, 2024, down from HKD 189,522 as of March 31, 2024[9] Expenses and Cost Management - Total expenses for business development decreased to HKD 2,783,000 from HKD 8,870,000, a reduction of 68.7%[19] - Interest expense on lease liabilities was HKD 635,000, down from HKD 1,211,000, reflecting a decrease of 47.5%[19] - Other expenses decreased from approximately HKD 20.6 million for the six months ended September 30, 2023, to approximately HKD 14.9 million for the same period in 2024, representing a reduction from 20.3% to 17.1% of revenue[61] - Business development expenses significantly decreased from approximately HKD 8.9 million in the six months ended September 30, 2023, to approximately HKD 2.8 million in 2024, primarily due to reduced promotional activities[64] - Professional fees increased by approximately HKD 2.9 million or 362.5%, from approximately HKD 0.8 million to approximately HKD 3.7 million, due to the hiring of additional professional services[64] - Employee benefit expenses decreased to approximately HKD 24.0 million for the six months ending September 30, 2024, from about HKD 29.2 million for the same period in 2023, representing 27.5% of revenue[56] Strategic Focus and Future Plans - The company continues to focus on enhancing its ophthalmic services and exploring potential market expansion opportunities[12] - The company plans to acquire equity interests in ophthalmology clinics and hospitals in China to expand its "Clear" brand business[84] - The company plans to identify suitable partners for collaboration and expansion[85] - The company aims to provide high-quality healthcare services while ensuring sustainable growth through strategic adjustments[35] - The company has extended the expected timeline for utilizing the allocated but unutilized net proceeds due to operational challenges and uncertainties regarding acquisition opportunities in the Greater Bay Area and potential partners in China[102] Corporate Governance and Compliance - The company has maintained a high standard of corporate governance and complied with applicable codes[96] - The board is actively seeking suitable candidates to fill the vacancy of independent non-executive directors to comply with listing rules[104] - The interim financial results for the six months ending September 30, 2024, will be published on the company's website and the Hong Kong Stock Exchange[105]
清晰医疗(01406) - 2025 - 中期业绩